Compare Marvell Technology Inc (MRVL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Marvell Technology Inc trades at $275.28 (market cap $246.84B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Marvell Technology Inc is far larger — about 9.8× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MRVL | RPRX | |
|---|---|---|
Market Cap | $246.84B | $25.27B |
Volume | 29,003,830 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $316.43 | $63.96 |
52-Week Low | $73.73 | $35.44 |
Typical Hold Time | 42 Days | 1 Days |
Enterprise Value | $248.19B | $32.50B |
Dividend Yield | 0.09% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $274.66, down 3.52% on the day, but maintains strong analyst support with 84% buy ratings and a $327.86 consensus price target. The stock shows bullish technical signals with support at $267 and resistance at $282, while recent earnings beats and projected revenue growth to $9.5B in 2026 highlight fundamental momentum. Management's raised 2028 revenue guidance to $18B and major hyperscaler deals underscore the company's positioning in AI infrastructure.
Outlook remains positive driven by AI chip demand and custom silicon growth, though high valuations (P/E 90.95) and margin pressures present risks. The stock offers significant upside to analyst targets but requires monitoring of execution against aggressive growth forecasts and competitive dynamics in the semiconductor space.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
